World Health Organization Issues Alert Over Critical Shortage of Weight-Loss Injections
Under 10% of patients who could benefit from weight-loss injections such as Wegovy are able to get them, states the World Health Organization as it issues its initial recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just access to these injectable treatments.
Per forecasts, over two billion are projected to be obese by 2030 without intervention.
"Our new guidelines affirms that obesity is a long-term condition that can be addressed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to widespread access to the jabs that can assist patients in reducing considerable body mass, notes the organization.
Skinny Jab Scarcity
Despite the present best projected case, the supply of such drugs might only reach around 100 million people – less than 10% of eligible patients, according to the WHO.
The guideline urges countries and companies to widen availability, by approaches such as patent sharing.
Exclusive production rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
The Way Obesity Drugs Function
The injections imitate a biological compound to delay gastric emptying, reduce hunger and boost the sense of being full so people consume fewer calories.
Individuals usually start to lose weight within a few weeks of commencing the weekly injections.
Evidence points to people may put most of the weight back on within a year of halting the drug, because their normal hunger resume.
To be above a healthy weight elevates your chance for contracting medical conditions, such as diabetes, heart disease, stroke, and some cancers.
Obesity impacts individuals in all nations and was associated with millions of fatalities worldwide in 2024, according to the health agency.
